Bio Medica Laboratories SME: Check IPO Date, Live Subscription and Key Details
Bio Medica Laboratories Limited, incorporated in 2015, is an Indian pharmaceutical manufacturer specializing in parenteral formulations. The company develops and contract-manufactures a wide range of ethical drugs, generic medicines, and over-the-counter (OTC) products in the form of liquid and dry powder injectables. Operating entirely on a B2B contract manufacturing model, it designs multi-dose and single-dose injectables for both human and veterinary applications. The company runs two specialized production facilities in Indore, Madhya Pradesh, certified for Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP).
Price Range
₹132.0 - ₹139.0
Issue Size
₹52.43 Cr
Lot Size
1,000 shares
IPO Type
NSE SME
GMP
₹4(+2.88%)
Est. Listing Price
₹143
Estimate Profit
₹8,000
Retail Portion
50.01%
Key Metrics
Check Live GMPGMPFace Value
₹10
EPS
10.33
P/E Ratio
13.45
RoNW
54.41%
ROE
54.41%
Debt to Equity
2.23
Advertisement
Timeline
IPO Opens
21 May
IPO Closes
25 May
Allotment
26 May
Listing
29 May
IPO Timeline & Listing Details
| Event | Date | Details |
|---|---|---|
| IPO Open Date | 21 May 2026 | Subscription starts |
| IPO Close Date | 25 May 2026 | Subscription ends |
| Allotment Date | 26 May 2026 | Allotment |
| Listing Date | 29 May 2026 | Listing |
Investment Categories
| Category | Lots | Amount |
|---|---|---|
Individual | 2 | ₹2,78,000 |
SHNI (Min) | 3 | ₹4,17,000 |
SHNI (Max) | 7 | ₹9,73,000 |
BHNIAbove ₹10,00,000 | 8 | ₹11,12,000 |
IPO Reservation Details
| Category | Reservation |
|---|---|
| QIB (Qualified Institutional Buyer) | 1.00% |
| NII (Non-Institutional Investor) | 48.98% |
| SHNI (Small Non-Institutional Investor) | 15.51% |
| BHNI (Big Non-Institutional Investor) | 31.02% |
| Retail | 50.01% |
| Market Maker | 5.01% |
| Total | 100.00% |
IPO Objectives
- Enhancement of its existing production capabilities by setting up a new manufacturing facility at the existing Indore premises (₹28.50 Cr).
- Repayment or prepayment of outstanding loans availed by the company (₹6.50 Cr).
- General Corporate Purposes.
Strengths
- The company has built a Diversified Parenteral Product Stack, featuring a broad formulation pipeline of 58 liquid and 15 dry powder injectable layouts spanning critical antibiotic and pain management therapeutics.
- It operates on a Pure B2B Contract Manufacturing Model, focusing entirely on institutional specialized processing lines that ensure custom specifications and sticky, long-term B2B linkages.
- The business boasts an Excellent Profitability Profile, demonstrating robust operational efficiencies with an impressive PAT Margin of 30.35% and a strong EBITDA margin of 47.11% (as of Nov 2025).
- It maintains Certified Regulatory Standings, operating out of dual production units in Madhya Pradesh backed by regulatory GMP and GLP standard approvals.
- The firm exhibits High Return Ratios, showcasing exceptional pre-IPO operational returns with an outstanding RoNW profile reaching 54.41%.
Weaknesses
- The company carries Significant Financial Leverage, with an aggressive debt burden of ₹38.17 Cr against a net worth of ₹17.12 Cr, driving a high debt-to-equity ratio of 2.23.
- There is a notable Client Concentration Risk, as business metrics rely heavily on strategic procurement agreements with a finite base of pharmaceutical players, leaving it exposed to client churn.
- The issue faces a Flat Initial Premium, with unofficial grey market sentiment sitting flat at ₹0, indicating a highly conservative local market reception ahead of launch.
- It operates with a Highly Constrained QIB Pool, where the QIB reservation is exceptionally small at 1.00%, shifting massive retail and NII dependency onto public absorption.
Advertisement
Financial Performance
| Period Ended | 30 Nov 2025 (8M) | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets (₹ Cr.) | 65.17 | 39.12 | 19.53 | 17.57 |
| Revenue (₹ Cr.) | 28.63 | 38.33 | 15.34 | 16.25 |
| PAT (₹ Cr.) | 8.66 | 9.79 | 2.5 | 0.33 |
| Net Worth (₹ Cr.) | 17.12 | 14.73 | 4.94 | 2.44 |
Peer Comparison
| Company | P/B Ratio | P/E Ratio | RONW (%) | Net Worth (₹ Cr.) |
|---|---|---|---|---|
| Bio Medica Laboratories Ltd. | 8.66 | 13.45 | 54.41% | 17.12 |
| Zenotech Laboratories Limited | 2.89 | 84.31 | -1.13% | 96.76 |
| Shukra Pharmaceuticals Limited | 15.31 | 62.8 | 24.54% | 63.43 |
Subscription Details
Daily Bids Status
| Category | Day 1 |
|---|---|
| QIB | 15.94x |
| NII | 0.03x |
| S-HNI | 0.06x |
| B-HNI | 0.01x |
| RII | 1.09x |
| Total | 0.72x |
Overall Subscription Statistics
| Category | Shares Offered | Shares Bid | Bid Amount (₹ Cr) |
|---|---|---|---|
| QIB | 36,000 | 5,74,000 | 7.98 |
| NII | 17,55,000 | 52,000 | 0.72 |
| Small NII | 5,85,000 | 36,000 | 0.5 |
| Big NII | 11,70,000 | 16,000 | 0.22 |
| RII | 17,92,000 | 19,60,000 | 27.24 |
| Total | 35,83,000 | 25,86,000 | 35.95 |
Advertisement
Company Details
- Bio Medica Laboratories Ltd.
- Plot No. 11B-11C, Sector-E, Sanwer Road Industrial Area, Industrial Estate (Indore), Indore, Madhya Pradesh, 452015
- +91 7314102751
- companysecretary@biomedica.co.in
- https://biomedica.co.in/
Registrar Details
- Skyline Financial Services Pvt.Ltd.
- 02228511022
- ipo@skylinerta.com
- https://www.skylinerta.com/
Frequently Asked Questions
What does Bio Medica Laboratories do?
Bio Medica Laboratories is a pharmaceutical company that manufactures parenteral formulations, including liquid and dry powder injectable products for human and veterinary use.
What are the IPO dates for Bio Medica Laboratories SME IPO?
The Bio Medica Laboratories SME IPO will open for subscription on May 21, 2026, and close on May 25, 2026.
What is the price band and minimum investment for Bio Medica Laboratories IPO?
The IPO price band is fixed at ₹132 to ₹139 per share. Retail investors need a minimum investment of ₹2,78,000 for 2,000 shares.
What is the Grey Market Premium (GMP) of Bio Medica Laboratories IPO today?
As of May 18, 2026, the Grey Market Premium (GMP) of Bio Medica Laboratories IPO is ₹0, indicating an expected listing price near ₹139 per share.
Where will Bio Medica Laboratories IPO be listed?
Bio Medica Laboratories IPO is proposed to be listed on NSE SME (NSE Emerge), with the tentative listing date set for May 29, 2026.
Loading comments...